Monte Rosa Therapeutics (GLUE) Non-Current Deferred Tax Liability (2024)

Monte Rosa Therapeutics (GLUE) posted quarterly Non-Current Deferred Tax Liability of $11.5 million for Q4 2024.

Monte Rosa Therapeutics (GLUE) Non-Current Deferred Tax Liability (2024) Analysis & Trends

Monte Rosa Therapeutics' Non-Current Deferred Tax Liability history runs 1 years deep, the most recent figure standing at $11.5 million for Q4 2024.

In Q4 2024, Non-Current Deferred Tax Liability changed N/A year-over-year to $11.5 million; the TTM figure through Dec 2024 stood at $11.5 million (changed N/A YoY), while the FY2024 annual figure was $11.5 million, changed N/A from the prior year.
Non-Current Deferred Tax Liability for Q4 2024 stood at $11.5 million.
The five-year high for Non-Current Deferred Tax Liability was $11.5 million in Q4 2024, with the low at $11.5 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Monte Rosa Therapeutics	1.32 Bn	688.11 Mn	-

Download Data

Date	Value
Dec 31, 2024	11.50 Mn
Dec 31, 2024	11.50 Mn